Samsung Bioepis Announces Results of Additional One-Year Follow-up Study on SB3 Trastuzumab Biosimilar Candidate at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Samsung Bioepis Co., Ltd. today announced additional one-year follow-up study results on SB3, a biosimilar candidate referencing Herceptin® 1 (trastuzumab). The data was made available as an abstract publication at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 1-5, 2018 in Chicago.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180601005020/en/
Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire)
“The additional one-year follow-up study demonstrates the long-term safety profile of SB3,” said Chul Kim, Head of Clinical Sciences Division, Samsung Bioepis. “We remain committed to advancing our strong pipeline of biosimilar candidates, so that more patients and healthcare systems can benefit from biosimilars.”
Patients with HER2-positive early breast cancer were randomly assigned to receive eight cycles of SB3 or reference trastuzumab (TRZ) in neoadjuvant setting concurrently with chemotherapy. Patients then underwent surgery, followed by 10 cycles of adjuvant SB3 or TRZ. After completion of therapy, 367 patients (SB3, n=186; TRZ, n=181) consented to participate in a five-year follow-up study. The median follow-up duration from initiation of study treatment was 30.1 months in SB3 and 30.2 months in TRZ. The aim of this study was to observe the incidence of symptomatic congestive heart failure (CHF), asymptomatic significant left ventricular ejection fraction (LVEF) decrease, incidence of other cardiac events, event-free survival (EFS), and overall survival (OS).
Throughout the additional one-year treatment-free follow-up period, the study results showed low incidence of cardiac safety events and no statistically significant difference in survival results compared to TRZ in the SB3 treatment group.
SB3 is under regulatory review by the US Food and Drug Administration (FDA). The Biologics License Application (BLA) for SB3 was accepted for review in December 2017.
Details on the abstract publication are as follows:
‘Additional one-year follow-up study to evaluate safety and survival
in patients who have completed neoadjuvant-adjuvant treatment with SB3
(trastuzumab biosimilar) or reference trastuzumab in HER2-positive
early or locally advanced breast cancer’
- Abstract Number: e12631
- Lead Author: Xavier Pivot
- URL: https://meetinglibrary.asco.org/record/163029/abstract
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six late-stage candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.
1 Herceptin ® is a registered trademark of Genentech
Samsung Bioepis Co., Ltd.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AETOSWire Launches Its Innovative Press Video Service20.6.2018 07:00 | Pressemelding
AETOSWire, the news distribution arm of News Services Group and the exclusive representative of Business Wire, a Berkshire Hathaway company, in the MENA region, launched the innovative Press Video Service that transforms textual press releases into a less than 60-Seconds Animated Press Video. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180620005113/en/ To keep pace with the ever-evolving and advancing communications landscape, AETOSWire always aim to anticipate the future needs of its clients and stakeholders. The Press Video is one of the latest services launched by AETOSWire along with a few most sought-after communication services, like the Audio Alerts for Journalists, to mark its 10 years in the industry. The Press Video came about as a response to the influx of press releases on various media outlets, whereby clients’ messages would get lost in the mound of press releases. With thousands of news available online, cl
Tigo Awarded Patent for Flex MLPE Platform20.6.2018 06:00 | Pressemelding
Tigo®, pioneer of the Smart Modular Flex MLPE platform, today announced that it has been granted its most important and industry strategic hardware patent applying to the smart technology used in its flexible module-level power electronics (Flex MLPE) within solar junction boxes. Tigo’s connection box with reliable and inexpensive contacts for solar modules is now patented to enable the use of multiple types of passive and active covers for different functionalities in the junction box. To learn more, Tigo will be displaying its Flex MLPE during Intersolar Munich 2018 from June 20th – 22nd with multiple OEM and distribution partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180619006499/en/ The Flex MLPE's contacts within the junction box allow for high current, exposure to extreme elements, and interchangeable covers. (Photo: Business Wire) U.S. Patent 9,991,843 is Tigo’s 56th patent issued by the U.S. Patent and Trad
Ant Financial to Share Full Suite of AI Capabilities with Asset Management Companies20.6.2018 01:10 | Pressemelding
Ant Financial Services Group (“Ant Financial” or “the Company”) today announced that the Company will share a full suite of AI capabilities with asset management companies in China to support their digital transformation. Following its successful launch last year, Caifuhao, an AI-powered corporate account on the Ant Fortune platform, has brought tangible benefits to 27 fund management companies. “By combining Ant Financial’s AI technologies with the capabilities of asset management companies in investor education and fund management, together we are making customized wealth management services more accessible for ordinary users,” said Eric Jing, Executive Chairman and CEO of Ant Financial. With the support of AI-powered services offered by their Caifuhao account, including operational optimization, content generation, compliance and risk management, 27 fund management companies have been able to increase their operational efficiency by 70% while reducing their overall costs by 50%. Add
Avalara Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares19.6.2018 21:20 | Pressemelding
Avalara, Inc. (NYSE: AVLR) today announced the closing of its initial public offering of 8,625,000 shares of common stock, including the full exercise by the underwriters of their option to purchase 1,125,000 additional shares of common stock, at a price to the public of $24.00 per share. The shares began trading on the New York Stock Exchange on June 15, 2018 under the symbol “AVLR.” Goldman Sachs & Co. LLC, J.P. Morgan, and BofA Merrill Lynch acted as book-running managers for the offering. JMP Securities, KeyBanc Capital Markets, and Stifel acted as co-managers. The offering was made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at 866-471-2526, or by email at firstname.lastname@example.org, or from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at
Unilever Calls on Content Creators and Distributors to Eradicate Stereotypes19.6.2018 17:42 | Pressemelding
Unilever is calling on content creators and distributors to act now to eliminate outdated stereotypes. The move marks the latest step in the company’s industry-leading Unstereotype initiative, which launched two years ago with the aim of eliminating harmful and diminishing portrayals of people across advertising. As part of its Unstereotype commitment Unilever is expanding that initiative across all forms of content and branded entertainment, and today announces a three-year multi-million-dollar deal with Rexona, the world’s biggest deodorant brand, and Simon Fuller’s XIX Entertainment. Rexona (also known as Sure, Degree and Shield depending on the country) will partner with NOW UNITED, the first ever global pop group comprised of 14 artists from 14 countries including Brazil, China, Germany, India, Philippines, Senegal, US and UK. Together, will co-create content across multiple channels that unites different cultures through the joy of dance, celebrating movement and inspiring people
Universal Laser Systems Expands Its Materials Database with Henkel, Hexcel and Saint-Gobain Materials19.6.2018 12:05 | Pressemelding
Universal Laser Systems (ULS) announces the addition of Henkel, Hexcel® and Saint-Gobain materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The Henkel, Hexcel and Saint-Gobain materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: Henkel Bergquist™ Gap Pad® VO Thermal Material Henkel Bergquist™ Hi-Flow® 105 Thermal Material Henkel LOCTITE® EA 7000 AERO Film Henkel Hysol® EA 9696 AERO Film Henkel Bergquist™ Sil-Pad A2000 Thermal Material Hexcel® HexForce® 353 Aramid Fabric Hexcel® HexForce® 282 Carbon Fabric Saint-Gobain CHEMFILM® DF100 Cast PTFE Film Saint-Gobain CHEMFILM® ETFE-E2 Extruded Fluoropolymer Film Laser processing notes, describing the results of the laser-material interaction fo